Literature DB >> 17715227

Production of pseudoinfectious yellow fever virus with a two-component genome.

Alexandr V Shustov1, Peter W Mason, Ilya Frolov.   

Abstract

Application of genetically modified, deficient-in-replication flaviviruses that are incapable of developing productive, spreading infection is a promising means of designing safe and effective vaccines. Here we describe a two-component genome yellow fever virus (YFV) replication system in which each of the genomes encodes complete sets of nonstructural proteins that form the replication complex but expresses either only capsid or prM/E instead of the entire structural polyprotein. Upon delivery to the same cell, these genomes produce together all of the viral structural proteins, and cells release a combination of virions with both types of genomes packaged into separate particles. In tissue culture, this modified YFV can be further passaged at an escalating scale by using a high multiplicity of infection (MOI). However, at a low MOI, only one of the genomes is delivered into the cells, and infection cannot spread. The replicating prM/E-encoding genome produces extracellular E protein in the form of secreted subviral particles that are known to be an effective immunogen. The presented strategy of developing viruses defective in replication might be applied to other flaviviruses, and these two-component genome viruses can be useful for diagnostic or vaccine applications, including the delivery and expression of heterologous genes. In addition, the achieved separation of the capsid-coding sequence and the cyclization signal in the YFV genome provides a new means for studying the mechanism of the flavivirus packaging process.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17715227      PMCID: PMC2168813          DOI: 10.1128/JVI.01112-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  39 in total

1.  A dengue virus serotype-1 DNA vaccine induces virus neutralizing antibodies and provides protection from viral challenge in Aotus monkeys.

Authors:  T J Kochel; K Raviprakash; C G Hayes; D M Watts; K L Russell; A S Gozalo; I A Phillips; D F Ewing; G S Murphy; K R Porter
Journal:  Vaccine       Date:  2000-07-15       Impact factor: 3.641

2.  A DNA vaccine expressing dengue type 2 virus premembrane and envelope genes induces neutralizing antibody and memory B cells in mice.

Authors:  E Konishi; M Yamaoka; I Kurane; P W Mason
Journal:  Vaccine       Date:  2000-01-06       Impact factor: 3.641

3.  Humoral and cellular immune response to RNA immunization with flavivirus replicons derived from tick-borne encephalitis virus.

Authors:  Judith H Aberle; Stephan W Aberle; Regina M Kofler; Christian W Mandl
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

4.  Japanese encephalitis DNA vaccine candidates expressing premembrane and envelope genes induce virus-specific memory B cells and long-lasting antibodies in swine.

Authors:  E Konishi; M Yamaoka; I Kurane; P W Mason
Journal:  Virology       Date:  2000-03-01       Impact factor: 3.616

5.  Generation and characterization of a mammalian cell line continuously expressing Japanese encephalitis virus subviral particles.

Authors:  E Konishi; A Fujii; P W Mason
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

6.  Production and characterization of vaccines based on flaviviruses defective in replication.

Authors:  Peter W Mason; Alexandr V Shustov; Ilya Frolov
Journal:  Virology       Date:  2006-05-18       Impact factor: 3.616

7.  Noncytopathic replication of Venezuelan equine encephalitis virus and eastern equine encephalitis virus replicons in Mammalian cells.

Authors:  Olga Petrakova; Eugenia Volkova; Rodion Gorchakov; Slobodan Paessler; Richard M Kinney; Ilya Frolov
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

8.  Construction and applications of yellow fever virus replicons.

Authors:  Christopher T Jones; Chinmay G Patkar; Richard J Kuhn
Journal:  Virology       Date:  2005-01-20       Impact factor: 3.616

9.  West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays.

Authors:  B S Davis; G J Chang; B Cropp; J T Roehrig; D A Martin; C J Mitchell; R Bowen; M L Bunning
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

10.  An infectious West Nile virus that expresses a GFP reporter gene.

Authors:  Theodore C Pierson; Michael S Diamond; Asim A Ahmed; Laura E Valentine; Carl W Davis; Melanie A Samuel; Sheri L Hanna; Bridget A Puffer; Robert W Doms
Journal:  Virology       Date:  2005-03-30       Impact factor: 3.616

View more
  29 in total

1.  The amino-terminal domain of alphavirus capsid protein is dispensable for viral particle assembly but regulates RNA encapsidation through cooperative functions of its subdomains.

Authors:  Valeria Lulla; Dal Young Kim; Elena I Frolova; Ilya Frolov
Journal:  J Virol       Date:  2013-09-04       Impact factor: 5.103

2.  The infectivity of prM-containing partially mature West Nile virus does not require the activity of cellular furin-like proteases.

Authors:  Swati Mukherjee; Tsai-Yu Lin; Kimberly A Dowd; Carolyn J Manhart; Theodore C Pierson
Journal:  J Virol       Date:  2011-08-31       Impact factor: 5.103

3.  Construction and characterization of a single-cycle chimeric flavivirus vaccine candidate that protects mice against lethal challenge with dengue virus type 2.

Authors:  Ryosuke Suzuki; Evandro R Winkelmann; Peter W Mason
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

4.  Pseudoinfectious Venezuelan equine encephalitis virus: a new means of alphavirus attenuation.

Authors:  Svetlana Atasheva; Dal Young Kim; Maryna Akhrymuk; David G Morgan; Elena I Frolova; Ilya Frolov
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

5.  An Infectious cDNA Clone of Zika Virus to Study Viral Virulence, Mosquito Transmission, and Antiviral Inhibitors.

Authors:  Chao Shan; Xuping Xie; Antonio E Muruato; Shannan L Rossi; Christopher M Roundy; Sasha R Azar; Yujiao Yang; Robert B Tesh; Nigel Bourne; Alan D Barrett; Nikos Vasilakis; Scott C Weaver; Pei-Yong Shi
Journal:  Cell Host Microbe       Date:  2016-05-16       Impact factor: 21.023

6.  Extension of flavivirus protein C differentially affects early RNA synthesis and growth in mammalian and arthropod host cells.

Authors:  Sabrina Schrauf; Christian W Mandl; Lesley Bell-Sakyi; Tim Skern
Journal:  J Virol       Date:  2009-08-19       Impact factor: 5.103

7.  Infection, dissemination, and transmission of a West Nile virus green fluorescent protein infectious clone by Culex pipiens quinquefasciatus mosquitoes.

Authors:  Charles E McGee; Alexandr V Shustov; Konstantin Tsetsarkin; Ilya V Frolov; Peter W Mason; Dana L Vanlandingham; Stephen Higgs
Journal:  Vector Borne Zoonotic Dis       Date:  2010-04       Impact factor: 2.133

Review 8.  Flavivirus methyltransferase: a novel antiviral target.

Authors:  Hongping Dong; Bo Zhang; Pei-Yong Shi
Journal:  Antiviral Res       Date:  2008-06-05       Impact factor: 5.970

9.  A trans-complementing recombination trap demonstrates a low propensity of flaviviruses for intermolecular recombination.

Authors:  Christian Taucher; Angelika Berger; Christian W Mandl
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

10.  Identification of mutated cyclization sequences that permit efficient replication of West Nile virus genomes: use in safer propagation of a novel vaccine candidate.

Authors:  Ryosuke Suzuki; Rafik Fayzulin; Ilya Frolov; Peter W Mason
Journal:  J Virol       Date:  2008-05-14       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.